Post-OTC Review Conditions Covered Under Proposed Monograph Procedures
This article was originally published in The Tan Sheet
Executive Summary
Companies seeking monograph status of OTC drugs marketed in the U.S. after the beginning of the OTC review would have to follow FDA's proposed new procedures for additional OTC conditions.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning